01710nas a2200385   4500000000100000008004100001260001300042653001500055653001600070653001100086653002500097653001000122653002100132653001100153653001100164653001100175653002800186653001200214653000900226653001500235653001500250653001600265100001800281700001400299700001300313700001600326700001700342700001300359245009800372856004100470300001000511490000700521520078200528022001401310       1992                            d  c1992 Sep10aAdolescent10aBCG Vaccine10aBrazil10aCase-Control Studies10aChild10aChild, Preschool10aFemale10aHumans10aInfant10aInjections, Intradermal10aleprosy10aMale10aPrevalence10aSkin Tests10aVaccination1 aRodrigues M L1 aSilva S A1 aNeto J C1 aAndrade A L1 aMartelli C M1 aZicker F00aProtective effect of intradermal BCG against leprosy; a case-control study in central Brazil.  uhttp://ila.ilsl.br/pdfs/v60n3a01.pdf  a335-90 v603 a<p>A case-control study was undertaken to evaluate the protective efficacy of intradermal BCG against leprosy in a high-endemic area of leprosy in central Brazil. Sixty-two cases and 186 controls were included in the study. Cases were all newly diagnosed leprosy patients under 16 years of age attending an outpatient health service, and all of them were schoolchildren. Three controls under 16 years old, frequency matched by sex and age group, were selected from schools geographically located in the area from which the cases came. The presence of BCG was negatively associated with leprosy, indicating a 5.3 risk of leprosy for those nonvaccinated and protective efficacy of 81%. Paucibacillary patients were more likely to have a BCG scar than multibacillary patients.</p>  a0148-916X